Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for symptomatic atrial fibrillation
ACTRN12621000208808Phase 2Recruiting
- Sponsor
- University of Adelaide
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change in AF symptom severity score, Change in AF burden and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12621000208808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000208808.